Table 4.

Estimates from a hierarchical Bayesian model of the sustained virological response rates at 4 weeks (SVR4) and at 12 weeks (SVR12) after completing therapy with daclatasvir and sofosbuvir, with or without ribavirin

Estimate	SVR4				SVR12
	As-treated		Intent-to-treat		As-treated		Intent-to-treat
Country	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Austria	97	87–100	92	81–99	98	89–100	88	75–96
Denmark	93	77–100	88	73–97	98	89–100	87	73–95
Spain	98	95–100	92	95–100	98	94–100	89	83–94
Sweden	96	79–100	90	73–100	97	85–100	87	72–96
Switzerland	82	56–97	82	59–94	82	57–97	84	64–93
UK	96	80–100	82	52–95	97	83–100	82	56–93
Overall	96	86–100	89	76–96	97	89–100	87	75–94

These estimates apply to patients with genotype 1 hepatitis C, previously treated and now with decompensated cirrhosis